Key Points {#FPar1}
==========

Summary of Product Characteristics data may underestimate the risk of adverse drug reactions.Continuous tolerability and safety surveillance is necessary to align approval data with real-life experience.Frequent risk evaluation of drugs by means of routine clinical data could provide a new quality of drug surveillance.

Introduction {#Sec1}
============

Based on submitted quality, efficacy and safety data, dozens of new agents are receiving approval to the pharmaceutical market every year. Despite their promising advantage to medical care, at the time of approval, there can be no certainty that these drugs are completely safe \[[@CR1]\]. Information about specific population groups can frequently be assumed to be missing as well as data about rare adverse drug reactions (ADRs) or drug interactions. It is therefore necessary to establish methods of large-scale post-marketing surveillance to gather real-life data especially with regard to safety issues. In most countries a spontaneous reporting system (SRS) for collecting data of suspected ADRs is used. Reported data are assessed by the responsible authority in a global database, which thus contains a vast data pool of ADRs relating to a wide range of drugs, in support of its main objective of generating signals of unknown, rare or serious ADRs \[[@CR2]--[@CR4]\]. This is a very cost-effective method. However, this kind of drug safety monitoring also has many limitations, the most frequently mentioned being the subject of underreporting. The mentioned reasons for this are manifold, including lack of time, large effort, fear of being prosecuted, unawareness of the requirement to report or the estimation that a particular ADR is not worth noting \[[@CR3]--[@CR5]\]. Also, SRSs are often believed to be exclusively designed for detecting rare and serious ADRs, but for general drug safety, the monitoring of all undesirable reactions is necessary \[[@CR4]\]. For the most accurate relative risk (RR) assessment, exact data of application or drug utilization is required, which, however, is only available by approximation. Thus, an SRS has not got the impact to determine the prevalence rate of a specific ADR reliably and bears a risk of delay in signal detection.

In the case of diseases requiring lifelong treatment, more detailed knowledge about the efficacy and tolerability of a drug, attention to ADRs as well as awareness of patients' needs are necessary to achieve the best therapeutic outcome. For epilepsy, as one of these diseases, the occurrence of ADRs has been shown to have an important influence on patients' quality of life \[[@CR6]--[@CR9]\]. Approximately 20 % of all patients with epilepsy, in the case of refractory epilepsy, even about 50 %, are on polytherapy, bearing an increased risk for ADRs and drug interactions \[[@CR10]--[@CR13]\]. Many of these patients have tried most of the available drugs and are therefore a target group for new treatment options aimed at reducing seizure frequency while maintaining or even optimizing tolerability. Especially in patients suffering from seizure recurrence, optimizing therapy can be a balancing act between increasing the drug dosage to maximize the therapeutic effect and running the risk of ADRs \[[@CR14], [@CR15]\]. Over the past 25 years, more than 15 new antiepileptic drugs (AEDs) with modified acting mechanisms and/or side effect profiles have become available for epilepsy treatment, resulting in a major challenge for health professionals and post-marketing surveillance in respect of specified knowledge about tolerability and drug interaction. Such a level of competence can hardly be generated by relying only upon a tool like an SRS for monitoring drug safety. In fact, long-term supervision of medicated patients, increased sensitivity towards recognizing accumulation of specific ADRs and deriving remedial measures from these observations are recommended as vital for a comprehensive risk--benefit evaluation \[[@CR14]\]. Accordingly, the systematic assessment and evaluation of routine inpatient data was assumed to be one way of obtaining this relevant knowledge and was therefore investigated in this survey.

Methods {#Sec2}
=======

Data Collection {#Sec3}
---------------

Between May 2008 and December 2010, an in-house pharmacist attended the Consultants' ward round once a week on four different wards of the Bethel Epilepsy Centre, Bielefeld, Germany, a tertiary reference center for epilepsy. All information taken as part of clinical routine during the ward round was documented in the patients' chart as usual and, for later digitalization, concurrently transcribed to an adjusted record form by the pharmacist. For every patient a new record form was used for each week. All inpatients receiving one of the newer AEDs, i.e., topiramate (TPM), levetiracetam (LEV), zonisamide (ZNS), pregabalin (PGB), extended-release oxcarbazepine \[OXC(ER)\], lacosamide (LCM) and eslicarbazepine (ESL), were included. Documented data comprised the specific drug, all AEDs in use, corresponding daily dosages and serum levels, if available, age, gender, concomitant medication, patient and actual case number. In addition, all patient-reported and medically diagnosed ADRs were documented in an unstructured format, and for each one, the current causality concerning the administered AEDs was assessed by interprofessional exchange (i.e., physician, pharmacist, nursing staff). To this end, the temporal pattern of association between its occurrence and change of medication and all available information concerning concomitant disorders, diseases or medication were taken into account. For the classification of causality, the WHO-UMC Causality Categories were used (see the electronic supplementary material, Online Resource 1) \[[@CR16]\]. Any severe or unknown suspected ADRs were immediately reported via the SRS to the responsible regulatory authority.

Data Entry {#Sec4}
----------

All relevant data were recorded by the pharmacist in an internal database, using IBM SPSS for Windows 20.0. Patient data were documented by assigning an individual patient number, case number, gender, age and date of observation. In order to enable the evaluation, the initially documented ADRs were coded numerically according to the system organ classes (SOCs) of the MedDRA (*Medical Dictionary for Regulatory Activities*) terminology, and the specific symptom. Also, corresponding causality categories were entered numerically. For every documented ADR and week, a single data set containing patient details, medication, daily dosage and causality category for every given AED was generated. Where the same ADR was documented more than once for one patient, the first documented observation and accordingly the one with the lowest AED dosages was included for analysis only. For patients without ADRs, the highest AED dosage was considered. To rule out possible input errors, the data were entered twice at different times. Asserted discrepancies were clarified by re-checking the record forms.

Data Evaluation {#Sec5}
---------------

Demographic and clinical characteristics of the patients were evaluated by using the first documented contact after hospitalization. For every newer AED, the total number of patients without and with ADRs, assessed with at least possible causality, and the corresponding dosages were calculated. Additionally, the same analysis was performed including only data sets of patients being treated off-label with regard to the maximum recommended daily dosage in the Summary of Product Characteristics (SmPC). In both analyses, every patient was included only once. Furthermore, for every AED, the incidence of the respective ADR was determined with reference to the number of patients experiencing this ADR while taking the particular AED divided by the total number of patients where this AED was part of the therapy. All estimated incidence rates were compared with the respective data provided in the SmPC of each AED \[[@CR17]--[@CR23]\]. The correlation between the number of AEDs and the total drug load, calculated as sum of the defined daily doses (DDDs), was determined by Spearman correlation. For assessing the impact of number of AEDs and sum of DDDs on the occurrence of ADR, logistic regression was used.

Concerning tolerability of each AED, the RR of ADR occurrence was calculated. For this purpose, the data of LEV were used as the reference, as being the most frequently applied AED in this survey, the first recommended for treatment of focal epilepsy out of this selection and also proven as well tolerated \[[@CR24]--[@CR28]\].

Results {#Sec6}
=======

In total, data of 562 cases were assessed, which equals around one quarter of the total number of in-house patients on the attended wards in the same time period. The corresponding patients' characteristics, length of stay and number of AEDs in concomitant usage \[mean, median and standard deviation (SD)\] are summarized in Table [1](#Tab1){ref-type="table"}. For further specification of the antiepileptic therapy, the number and percentage distribution of patients receiving antiepileptic monotherapy versus polytherapy of up to six different AEDs were evaluated on the basis of each initially documented observation per patient. Hence, 57 patients (10.1 %) were on monotherapy, 192 patients (34.2 %) were treated with two different AEDs, 205 patients (36.5 %) with three, 88 (15.7 %) with four, 19 (3.4 %) with five and just one patient (0.2 %) with six. The number of AEDs correlated significantly with the total drug load as sum of DDDs (*r*~s~ = 0.661, *p* \< 0.001). The mean drug load (± SD) per patient increased with an increasing number of AEDs from 1.15 ± 0.60 in patients on monotherapy to 2.42 ± 0.98 in patients on two concomitant AEDs, 3.33 ± 1.33 in those on three, 4.50 ± 1.35 in those on four and 5.56 ± 1.28 in those on five or six.Table 1Patients' characteristics^a^ of 562 in-house patients treated at the tertiary reference center for epilepsy who were receiving at least one of the newer AEDs*N*Total (%)MeanMedianSDMin.Max.Gender Male29352.1 Female26947.9Epilepsy syndrome Focal44679.4 Generalized8314.8 Focal + generalized244.3 Non-epileptic disorder^b^91.6Age (years)56237.236.014.616.089.0Length of stay (days)56260.651.038.76.0238.0No. of AEDs per patient5622.643.001.001.006.00Drug load of AEDs (DDD)^c^5623.143.021.530.2510.82*AED* antiepileptic drug, *DDD* defined daily dose, *SD* standard deviation^a^Calculated by including every first documented observation of each patient^b^Differential diagnosis of a paroxysmal non-epileptic disorder obtained during hospitalization^c^Sum of DDD according to the WHO DDD list

In monotherapy, as well as in a combination of two different AEDs, OXC(ER) and LEV were the ones most commonly used. This is the case for more than 40 % of the patients. For further information concerning the percentage of each AED in antiepileptic polytherapy see Fig. [1](#Fig1){ref-type="fig"}. LEV and OXC(ER) were further the most frequently used at all, with applications documented for 367 and 183 patients, respectively. For TPM and LCM, the data of 109 and 102 patients were assessed, whereas ZNS (68 patients), PGB (61 patients) and ESL (17 patients) were a less frequently used component of the antiepileptic therapy.Fig. 1Percentage of patients treated with the respective AED, stratified by monotherapy and the different kinds of polytherapy (*left to right*). Total percentage of patients taking respective drug either as monotherapy or part of polytherapy: LEV 66.19 %, OXC(ER) 32.38 %, TPM 19.4 %, LCM 18.15 %, ZNS 12.1 %, PGB 10.68 %, and ESL 3.02 %. *AED* antiepileptic drug, *ESL* eslicarbazepine, *LCM* lacosamide, *LEV* levetiracetam, *OXC(ER)* oxcarbazepine extended-release formulation, *PGB* pregabalin, *TPM* topiramate, *ZNS* zonisamide

In total, ADRs of AEDs were documented for 318 patients (56.6 %). Logistic regression indicated that the occurrence of ADRs was significantly associated with the number of AEDs in polytherapy regime (*p* \< 0.001) as well as the total drug load as sum of DDDs (*p* = 0.003), whereas each predictor was analyzed separately.

For each of the focused AEDs, the number of cases without and with an ADR of at least possible causality and corresponding dosages are listed in Table [2](#Tab2){ref-type="table"}. For none of these AEDs the sum of percentage of cases without and with possibly related ADRs achieved 100 %. The differences, ranging from 4 to 15 %, represent ADRs assessed as unlikely, conditional or not causally linked to the particular AED. In the case of TPM, this applied to 13 patients, for LEV to 44, PGB to seven, ZNS to ten, OXC(ER) to 13, LCM to ten and ESL to just one patient.Table 2Patients without and with at least possibly related ADRs, stratified by the respective AEDs, including details of particular daily dosages*N*Total^a^ (%)RR^b^CIDaily dosage (mg)MeanMedianSDMin.Max.LEV Without ADR20355.3\[1.00\]2596300011072506000 With possible ADR12032.72465250010962507000PGB Without ADR2642.61.310.89--1.9348760018775750 With possible ADR2845.932127519475750ZNS Without ADR2638.21.400.98--2.0225625016450600 With possible ADR3247.1338300148100600OXC(ER) Without ADR7339.91.571.26--1.95171518006774503850 With possible ADR9753.0164618005304503000LCM Without ADR3736.31.631.24--2.1332635014450600 With possible ADR5553.926925013950600TPM Without ADR3128.41.971.56--2.4722315020325800 With possible ADR6559.621320011950500ESL Without ADR211.82.301.75--3.021800180084912002400 With possible ADR1482.4151416005018002400*AED* antiepileptic drug, *ADR* adverse drug reaction, *CI* confidence interval, *ESL* eslicarbazepine, *LCM* lacosamide, *LEV* levetiracetam, *OXC(ER)* oxcarbazepine extended-release formulation, *PGB* pregabalin, *RR* relative risk for the occurrence of possibly related ADRs compared with the occurrence of these under levetiracetam, *SD* standard deviation, *TPM* topiramate, *ZNS* zonisamide^a^For calculation, the total number of documented cases per AED was used; the missing percentage up to 100 % fall upon ADRs assessed as unlikely, conditional or not causally linked to the particular AED^b^For calculation of RR, patients taking both of the specifically compared AEDs were excluded

By referring exclusively to the overall tolerability, LEV emerged as best tolerated. The calculated RRs of ADR occurrence per AED compared with LEV, which was set as reference, ranged between 1.31 and 2.30, whereas again just the total number of possibly related ADRs was taken into account, not the clinical relevance of every single ADR nor other tolerability influencing factors.

By means of the maximum applied dosages (Table [2](#Tab2){ref-type="table"}), it becomes apparent that in some cases the maximum applied AED dosage exceeded the maximum permissible dosage according to the particular SmPC \[[@CR17]--[@CR23]\]. For LCM, that dosage was specified as 400 mg per day, for TPM and ZNS, as 500 mg/day each, and for PGB, as 600 mg/day; for ESL, OXC(ER) and LEV, the maximum approved dosage was determined as 1200, 2400 and 3000 mg/day, respectively. The proportion of off-label usage concerning the maximum recommended daily dosage in the SmPC varied between 6.4 and 64.7 % with regard to the total number of patients the respective AED was part of therapy. For further differentiation, the corresponding data of every single AED, with and without ADR, is summarized in Table [3](#Tab3){ref-type="table"}. Comparing the calculated RR for each AED used off-label to its application as recommended by the SmPC revealed no relevant risk change. Though, the number of patients for these evaluations was small.Table 3Patients under off-label use concerning dose, without and with at least possibly related ADRs, stratified by the respective AEDs, including details of particular daily dosages*N*Total^a^ (%)RRCIDaily dosage (mg)MeanMedianSDMin.Max.TPM Off-label use**7**6.4 Without ADR43.70.490.16--1.54638600111550800 With possible ADR21.865065071600700LCM Off-label use1817.6 Without ADR87.80.840.50--1.4051350058450600 With possible ADR87.850050053450600LEV Off-label use9124.8 Without ADR5013.60.950.68--1.333945400040835006000 With possible ADR277.44102400070135007000PGB Off-label use69.8 Without ADR34.90.960.42--2.2472575043675750 With possible ADR34.970870038675750OXC(ER) Off-label use20**10.9** Without ADR84.41.020.68--1.522994300040125503850 With possible ADR116.02832270031625003600ESL Off-label use11**64.7** Without ADR15.91.030.78--1.362400240024002400 With possible ADR952.91822160035316002400ZNS Off-label use710.3 Without ADR22.91.210.66--2.236006000600600 With possible ADR45.958860025550600*AED* antiepileptic drug, *ADR* adverse drug reaction, *CI* confidence interval, *ESL* eslicarbazepine, *LCM* lacosamide, *LEV* levetiracetam, *OXC(ER)* oxcarbazepine extended-release formulation, *PGB* pregabalin, *RR* relative risk for the occurrence of possibly related ADRs comparing off-label use concerning dose to the particular applications of the same drug used on-label, i.e., according to the recommended dosage by the Summary of Product Characteristics, *SD* standard deviation, *TPM* topiramate, *ZNS* zonisamide^a^For calculation, the total number of documented cases per AED was used

Concerning the documented ADRs, the most common were related to electrolyte imbalance, e.g., low sodium (*n* = 79, 14.1 %) and potassium (*n* = 25, 4.4 %) levels, the central nervous system, including dizziness (*n* = 61, 10.9 %), disturbed vision (*n* = 47, 8.4 %), fatigue (*n* = 40, 7.1 %), nystagmus (*n* = 36, 6.4 %) and ataxia (*n* = 29, 5.2 %), or cognitive deficits, especially disturbance of speech (*n* = 37, 6.6 %), memory impairment (*n* = 36, 6.4 %) and mental slowing (*n* = 32, 5.7 %). In 24 patients (4.3 %), the observed ADRs were considered as severe, rare, very distinctive or currently unknown and therefore reported via the SRS to the responsible regulatory authority. Among these reports were one case of an arrhythmia absoluta under the combination of LCM and LEV as a potentially life-threatening ADR, three of suicidal ideation (two under LEV, one under the combination of OXC(ER)/LCM), three of myoklonia \[two under OXC(ER), one under LEV\], two of peripheral edema under OXC(ER), one of paresthesia under LEV, one of anorexia under TPM and one case of anxiety under LEV.

For comparing the frequency of occurrence of particular ADRs in relation to the information mentioned in the SmPC, the incidence of the ADR was calculated for each AED separately. The detailed results are shown in Table [4](#Tab4){ref-type="table"}. Although, SmPC data express a very rough classification for ADR frequency by using categories differing by one power of ten only, e.g., ≥0.1 % for an uncommon and ≥10 % for a very common occurrence, for some registered ADRs probable underestimation was assumed. This, for example, was apparent in the case of cognitive impairment related to TPM and electrolyte imbalance concerning potassium under therapy with an carbonic anhydrase (CA) inhibitor (i.e., TPM, ZNS) or sodium level by application of dibenzazepine anticonvulsants (i.e., OXC, ESL).Table 4Incidence rates of all ADRs, assessed as at least possibly related to the antiepileptic drug, compared with corresponding frequency data by the SmPC (nonexhaustive list; occurred ADRs mentioned only)TPMLEVPGBZNSOXC(ER)LCMESLObs.SmPCObs.SmPCObs.SmPCObs.SmPCObs.SmPCObs.SmPCObs.SmPC*Metabolism and nutrition disorders*Weight gain *N*372 %≥10.8≥0.111.3≥1N/A1.1N/AN/AN/AWeight loss *N*923 %8.2≥100.5≥0.1≥0.14.5≥1N/AN/A≥0.1Decreased appetite/anorexia *N*553 %4.5≥11.4≥1N/A4.5≥1N/AN/A≥1Hypokalemia *N*1139131 %10.1≥0.10.8N/A≥0.113.2≥0.10.6N/A2.9N/A5.9N/AHyponatremia *N*3167310 %N/A0.8≥0.011.6N/AN/A37.0≥12.9N/A58.8≥1*Psychiatric disorders*Sleep disturbance/insomnia *N*2111 %≥10.5≥11.6≥11.5≥1N/A≥15.9≥1Nervousness/agitation *N*1511341 %0.9≥11.4≥11.6≥0.11.5≥101.7≥13.9≥0.15.9≥0.1Irritability *N*2101 %1.8≥12.7≥1≥1≥100.6N/A≥1≥0.1Aggressive reaction *N*2111221 %1.8≥13.0≥11.6≥0.13.0≥0.11.1N/A1.0≥0.1N/AAnxiety *N*41 %≥11.1≥11.6N/A≥1N/AN/AN/AListlessness/apathy *N*211 %≥0.10.5N/A1.6N/AN/A0.6≥1N/A≥0.1Mood swings/depressed mood *N*28312 %1.8≥102.2≥1≥0.14.5≥100.6≥11.9≥1≥0.1Confusion *N*21 %≥10.5≥0.1≥1≥100.6≥1≥1≥0.1Suicidal ideation *N*1411 %0.9≥0.11.1≥1N/A≥0.10.6N/A1.0≥0.1N/A*Nervous system disorders*Fatigue/tiredness *N*525561262 %4.5≥106.8≥108.1≥109.0≥106.6≥105.8≥111.8≥10Dizziness *N*5237524255 %4.5≥106.3≥111.3≥17.5≥1013.3≥1024.3≥1029.4≥10Nystagmus *N*4105213194 %3.6≥12.7N/A8.1≥0.13.0≥17.2≥118.4≥123.5≥0.1Tremor *N*21732381 %1.8≥14.6≥14.8≥13.0≥11.7≥17.8≥15.9≥1Balance disorder/ataxia *N*3102212112 %2.7≥12.7≥13.2≥13.0≥106.6≥110.7≥111.8≥1Disturbance in concentration/attention *N*163221 %14.7≥10.8≥0.1≥13.0≥11.1≥11.0≥1≥1Memory impairment *N*25112632 %22.9≥13.0≥0.13.2≥19.0≥101.7≥11.9≥1≥0.1Disturbance of speech *N*314342 %28.4≥11.1N/A≥0.14.4≥12.2N/A1.9≥1≥0.1Mental slowing/bradyphrenia *N*17101844 %15.6≥12.7N/A1.6≥0.111.9≥12.2N/A3.9≥1N/AHeadache *N*161741 %0.9N/A1.6≥101.6≥10N/A3.9≥103.9≥105.9≥1Dysgeusia *N*11 %≥10.3N/A1.6≥0.1N/AN/AN/AN/AParesthesia *N*32 %2.7≥100.5N/A≥1≥1N/A≥1≥0.1*Eye disorders*Blurred vision/diplopia *N*6135523174 %5.5≥13.5≥0.18.1≥17.5≥1012.6≥1016.5≥1023.5≥1*Ear and labyrinth disorders*Tinnitus *N*11 %0.9≥10.3N/AN/AN/AN/A≥1≥0.1*Gastro-intestinal disorders*Nausea/vomiting *N*34113152 %2.7≥101.1≥11.6≥1≥17.2≥1014.6≥1011.8≥1Diarrhea *N*111 %0.9≥100.3≥1≥1≥1≥11.0≥1≥1Obstipation *N*11242 %0.9≥1N/A1.6≥13.0≥12.2≥11.9≥1≥0.1Flatulence *N*14 %≥0.1N/A≥1N/A0.6N/A3.9≥1≥0.1*Hepatobiliary disorders*Increase in liver enzymes *N*612622 %≥0.11.6≥0.11.6≥0.13.0≥13.3≥0.11.9≥0.111.8≥0.1*Skin and subcutaneous tissue disorders*Hypersensitivity/pruritus *N*211 %≥10.5≥0.01≥0.1≥10.6≥0.0011.0≥1≥0.1Alopecia *N*1221 %0.9≥10.5≥0.01N/A≥11.1≥11.0N/A≥0.1*Musculoskeletal disorders*Myoclonia *N*112 %≥10.3N/A≥0.11.5N/A1.1N/A≥1N/A*General disorders*Peripheral edema *N*421 %N/AN/A6.5≥1≥11.1N/AN/A5.9≥0.1Total *N*109367616818310217 %100100100100100100100*ADR* adverse drug reaction, *ESL* eslicarbazepine, *LCM* lacosamide, *LEV* levetiracetam, *N/A* not available, *Obs.* observed, *OXC(ER)* oxcarbazepine extended-release formulation, *PGB* pregabalin, *SmPC* Summary of Product Characteristics, *TPM* topiramate, *ZNS* zonisamide

Discussion {#Sec7}
==========

AED Usage and ADR Incidence {#Sec8}
---------------------------

Of the various AEDs of interest in this survey, OXC(ER) and LEV were most frequently used. To our knowledge, no study has so far investigated this selection of newer AEDs, but there are three different papers reporting on the nation-wide prescription patterns of AEDs in Italy (data included until 2007), Norway (until 2009) and Germany (until 2010) \[[@CR13], [@CR29], [@CR30]\]. Extracting the data related to the AEDs focused on in this survey also reveals the tendency towards LEV being the most frequently used, followed by OXC(ER), TPM, ZNS and PGB. LCM and ESL were the most recently approved AEDs, which is why no reliable data were available.

With regard to every first documented observation per patient in this evaluation, almost 90 % were on polytherapy. Compared with the studies of Canevini et al. and Malerba et al. in which 22.5 and 21 %, respectively, of drug refractory patients were being managed on a single AED \[[@CR30], [@CR31]\], a proportion of 10.1 % is small. However, in our survey only patients recently admitted to in-house treatment were included, for whom, other than severe epilepsy, the need for a complex therapy management, including administration of antiepileptic medication for acute use and the change in therapy by gradual cross-over of AEDs, can be assumed. By considering the calculated mean data for the length of stay, number of concomitant AEDs and AED load, defined as the sum of DDDs (Table [1](#Tab1){ref-type="table"}), this assumption can be substantiated.

It is still a matter of debate if antiepileptic polymedication compared with monotherapy is generally associated with more frequent ADRs. The correlation between AED toxicity and total drug load rather than the number of concomitant AEDs is also still under discussion \[[@CR31]--[@CR34]\]. In this survey, both factors were significantly associated with a more frequent occurrence of ADRs, whilst also both were strongly correlated with each other. However, in view of the numerical extent of association, the total number of AEDs seemed to be of greater impact. The reasons for this can be manifold, including the absence of a rigid dosing scheme, a gradual cross-over of AEDs, and the value of DDD as an imperfect measure of drug exposure itself \[[@CR15], [@CR31], [@CR35]\]. Testing for serum concentration-dependent tolerability was also considered for this survey, but ultimately rejected as therapeutic drug monitoring of the newer AEDs often was applied in selected cases only \[[@CR36]\] and, therefore, corresponding serum concentrations were not available in every documented data set.

The overall incidence of ADRs was calculated as 56.6 %, based on 318 patients for whom adverse reactions were documented. With regard to the method of assessment and the investigated patient population, this result corresponds well with that of other studies. Canevini et al., who also analyzed patients with drug-resistant epilepsy at tertiary referral centers, identified ADRs in 36.5 % of patients, based on spontaneous reporting, compared with 95.5 % when a validated screening questionnaire was used \[[@CR31]\]; similar results were summarized in a review of Perucca and Gilliam \[[@CR37]\]. Considering that the detection of ADRs in clinical routine is derived from spontaneous reporting complemented by medical examination and lab diagnostics, and in view of the findings by Baker et al., which indicate a prevalence underestimation of ADRs when based on spontaneous reporting versus overestimation when using checklists, the extent of prevalence in this survey can be considered plausible for a real-life hospital setting \[[@CR38]\].

Concerning the overall tolerability, LEV emerged as best tolerated, which, similarly, was reported by Cramer et al. \[[@CR28]\]. This may be a reason for it being first recommended and therefore frequently used, as also indicated by the high number of patients under LEV in this survey. The calculated RRs of ADR occurrence for each AED compared with LEV varied between 1.31 and 2.30. But these values should be treated with caution; for the evaluation, only the total number of possibly related ADRs was taken into account, and not the type nor the clinical relevance of the ADR, nor other tolerability influencing factors. The impact of associated ADRs can be very different, which is why by using this kind of RR calculation only the overall tolerability can be estimated and has to be reviewed in every single case \[[@CR31], [@CR37]\]. Furthermore, all patients were preselected due to real-life conditions, and the total number of patients treated with particular AEDs varied widely, which in itself may have had an impact on the estimated RR.

An interesting finding of this survey was the rather high proportion of off-label use concerning maximum recommended daily dosage (Table [3](#Tab3){ref-type="table"}). So far, there are not many studies investigating off-label use by dose in drug resistant epilepsy. One study by Franco et al. focused on this question by means of a diagram, showing proportions of off-label use of between 0 and 25 % \[[@CR39]\]. The values in our survey ranged from 6.4 % for TPM up to 64.7 % for ESL. By comparing the calculated RR for each AED used off-label to its application as recommended by the SmPC, no considerable change of ADR occurrence was seen. However, the documented extent of off-label use showed an obvious relevance for clinical practice, indicating the need of further investigations on potential risks and benefits to alleviate physicians' and patients' uncertainty whilst using a drug out of its specification \[[@CR39]\].

As already mentioned, antiepileptic therapy often means a balancing act between optimizing therapeutic outcome and running the risk of ADRs \[[@CR6]--[@CR8], [@CR14], [@CR15], [@CR31], [@CR37], [@CR40]--[@CR42]\]. It is therefore important to be aware of the side effect profiles of every considered AED in order to choose the best therapy option for every patient. The comparison of incidences of ADRs with possible causality in relation to the information mentioned in the SmPC, which, to our knowledge, was first performed in this survey, is very valuable to provide a supplementary assessment of particular risk. Even though, SmPC data present a very rough estimate for ADR frequency by using categories differing by one power of ten only, e.g., ≥0.1 % for an uncommon and ≥10 % for a very common occurrence, for some of the documented ADRs, a probable underestimation was determined. For example, in the case of cognitive impairment related to TPM or electrolyte imbalance under therapy with a CA inhibitor (i.e., TPM, ZNS) or dibenzazepine anticonvulsants (i.e., OXC, ESL), the discrepancy was particularly apparent.

It is a well known fact that the detection of specific ADRs can be influenced by physicians' expectations as to the likelihood of occurrence \[[@CR8], [@CR31]\]. Therefore, it cannot be excluded that applied targeted testing, such as close control of lab values, will cause a detection bias.

TPM and ZNS are known as inhibitors of CA, which has a considerable share in regulating the acid--base balance and therefore influences the electrolyte status. In this survey, low potassium levels (\<3.6 mEq/L) were assessed for 11 and nine patients on TPM and ZNS (10.1 and 13.2 %), respectively, although the SmPC of both drugs mention this to be an uncommon occurrence (≥0.1 and \<1 %) \[[@CR17], [@CR20]\]. A similar result for TPM was found in a systematic review by Dell'Orto et al., indicating hypokalemia as concomitant with metabolic acidosis for 10 % of the cases \[[@CR43]\]. To our knowledge, there are no comparable investigations referring to potassium levels under ZNS treatment, but a study by Mirza et al. indicated similar inhibitor potency to CA isoforms by TPM and ZNS, both inducing renal tubular acidosis \[[@CR44]\]. Therefore, it seems plausible to detect an also increased frequency of hypokalemia under ZNS. Further investigations are definitely necessary to verify these results, but until then, the potential risk of CA inhibitors should be considered, particularly in patients with co-morbidity or co-medication influencing electrolyte balance.

The same applies to treatment regimes with OXC(ER) or ESL, for which a higher incidence of hyponatremia, compared with SmPC data, was documented \[[@CR21], [@CR23]\]. As possible reasons, the previously mentioned detection bias or other influencing factors, like vomiting, diuretic or psychotropic medication, heart or kidney insufficiency, etc., should be also taken into account. Furthermore, the varying reference values applied for the definition of hyponatremia in different studies (here \<135 mEq/L) and the highly selected patient population in this survey should be considered. Apart from this, there are many studies mentioning the frequency of decreased sodium serum levels in about 10--30 % of the patients under OXC treatment, which in turn substantiates an assumed higher risk \[[@CR45]--[@CR50]\]. At the time of approval, ESL was promoted as bearing a lower hyponatremia risk compared with OXC. However, studies by Ley et al. and Gupta et al. could not substantiate this claim \[[@CR51], [@CR52]\]. In our survey, almost all patients with ESL stopped OXC(ER) because of decreased sodium levels prior. Therefore, the previous experience of hyponatremia could be an explanation for the high incidence even under ESL. But interesting in this context, data concerning hyponatremia mentioned in the SmPC have, since approval, been adjusted to a common frequency (≥1 and \<10 %), therefore, indicating the same risk as for OXC(ER), by now \[[@CR23], [@CR53]\].

With regard to cognitive impairment (e.g., psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-finding difficulties), this is a well described problem in patients on TPM \[[@CR42], [@CR54]--[@CR59]\]. Being aware of that, neuropsychological testing and retesting (investigating cognitive processing, memory, language) are more often applied in conjunction with TPM therapy, as for example, recommended by Lee et al. \[[@CR60]\]. This may have induced an overestimation of the particular risk in this survey, since cognitive impairment is also known to be influenced by seizure frequency and an increased number and dosage of AEDs \[[@CR56]\]. However, a review by Mula, investigating the evidence of cognitive impairment under TPM, established that approximately 10 % of the patients experienced cognitive problems \[[@CR58]\]. Of these, as also confirmed in our survey, speech problems mainly concerning verbal fluency were the most prominent \[[@CR58], [@CR61]\], a fact, which should be considered in individual treatment plans, especially for patients actively working or studying.

In conclusion, the results of this survey show that a systematic evaluation of inpatient data allows for even more information to be gained than could be extracted from clinical trials or SRS. Therefore, this kind of surveillance can provide a decisive contribution to future adjustments of risk data, applied to align approval data with real-life experience, which is an ongoing process, as the comparison of SmPC data from 2011 and 2015 reflects \[[@CR17]--[@CR23], [@CR53], [@CR62]--[@CR67]\].

Methodological Considerations {#Sec9}
-----------------------------

Within this project, data were collected weekly by a pharmacist as part of the Consultants' ward rounds. It cannot be excluded that short-stay patients were missed, which could have biased the selection of patients towards more complex therapies. For this reason and to avoid time-consuming re-documentation of paper notes, the implementation of electronic patient records is to be recommended. For ADR documentation, no standardized questionnaire was used in this survey, which may have underrated some ADR incidences. However, by using this method, the ADR assessment remained as close to clinical routine as possible, and is therefore assumed to reflect the problems and concerns of practical relevance. A challenge, which is inherent in the system, is the real-life data assessment itself. Influencing factors, such as dose adjustment, change of therapy regime, co-morbidity or concomitant drug use, etc., do not follow a precise study plan under these conditions. Thus, the causality assessment and calculation of RRs concerning ADR are only methodical approaches to deal with these data, and the corresponding results should be judged in context and treated with caution. Due to this, not every pointed question of scientific interest can be proven or rejected. Moreover, neither the applied method nor all of the results can be translated to patients treated at primary care level or those being well controlled concerning seizure frequency and tolerability. But by this approach, treatment issues relevant to all patients can be identified and used as guidance for further investigation.

The major advantage of this method lies in the prospectively orientated full assessment of patients. It provides reliable application data, and the rather long-term observation period, the accumulation of medical information and the opportunity of monitoring progress, encourage the evaluation of causal relations between ADRs and suspected drugs.

Conclusion {#Sec10}
==========

For patients depending on lifelong treatment, optimized therapies adapted to individual needs are of great importance. For this purpose, established expertise in the advantages and disadvantages of each drug is indispensable. It has been shown that during inpatient treatment, valuable data are generated. A systematic assessment and continuous evaluation of these data can constitute a chance for perpetual risk and treatment evaluation under real-life conditions and therefore support individualized therapy management. Accordingly, even if this approach may need more methodological reasoning, it would certainly provide a new quality of drug surveillance.
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